Integer Holdings Corp
ITGR
ISIN null / Valor 33080752
Integer Holdings Corp
UMushroom community rating:
About company
Integer Holdings Corp is a leading medical device technology company that designs and manufactures a wide range of products, including catheters, guidewires, implantable ports, neuromodulation devices, and pacemaker batteries. With expertise in medical device development and battery design, Integer serves various markets, providing innovative solutions to medical device OEMs. The company's brands, such as Greatbatch Medical® and Lake Region Medical®, have a strong reputation for delivering high-quality products. With a history of industry-changing innovations and manufacturing excellence, Integer continues to be a trusted partner in the medical device industry, offering expertise in cardiac rhythm, cardio and vascular health, neuromodulation, and portable power solutions.
Summarized from source with an LLMView SourceSector: FinanceLatest Results (21.11.2025):
Integer Holdings Corp — Third Quarter 2025: Integer reported continued top‑line and adjusted profit growth for 3Q25, with sales up 8% year‑over‑year to $468 million (organic +7%). GAAP operating income modestly declined while non‑GAAP (adjusted) operating income, adjusted EBITDA and adjusted net income showed double‑digit percentage gains. The company updated its full‑year 2025 guidance and provided preliminary outlooks for 2026 and 2027.
Sales
3Q25 sales were $468 million, an 8% increase versus 3Q24, with organic growth of 7%.
GAAP vs. Non‑GAAP Profitability
GAAP operating income decreased $2 million to $56 million (‑3%), while non‑GAAP adjusted operating income rose $10 million to $86 million (+14%).
Net Income and EPS
GAAP income from continuing operations increased to $40 million (+9%), and GAAP diluted EPS was $1.11 (+10%). Non‑GAAP adjusted net income increased to $63 million (+27%) and adjusted EPS was $1.79 (+25%).
EBITDA and Cashflow
Adjusted EBITDA increased 11% to $106 million. Full‑year 2025 adjusted EBITDA guidance is $398–$404 million. Projected 2025 cash flow from operations (GAAP) is $230–$240 million.
Balance Sheet and Leverage
Total debt rose $204 million year‑to‑date to $1.194 billion (Non‑GAAP net total debt $1.158 billion), primarily to finance acquisitions and costs tied to the 2030 convertible note offering; leverage was 3.0x adjusted EBITDA as of September 26, 2025.
Product Line Performance
Cardio & Vascular sales +15% (new product ramps and acquisitions); Cardiac Rhythm Management & Neuromodulation +2% (emerging neuromodulation PMA customers); Other Markets ‑16% (planned exit from portable medical products).
2025 Outlook
Updated 2025 guidance: reported sales $1,840–$1,854 million (7–8% growth); GAAP operating income $220–$226 million; adjusted operating income $319–$325 million (+12–14%); adjusted EPS $6.29–$6.43 (up ~19–21%).
Preliminary 2026–2027 Outlook
Preliminary 2026 outlook: reported sales down 2% to up 2%, organic sales flat to up 4%, adjusted operating income down 5% to up 4% and adjusted EPS down 6% to up 5% (vs. 2025). 2027 target: return to organic growth ~200 basis points above market.
Management Commentary
CEO Joseph Dziedzic highlighted strong quarter-to-quarter adjusted growth and said select headwinds are expected in 2026, but the company expects a return to above‑market organic growth in 2027 driven by its product pipeline.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2453 M
Market cap (USD)
591,019
Daily traded volume (Shares)
134.22 / 131.92
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
